CFDE Data Portal | Search UBE2Q1-AS1

	Label	Description
	UBE2Q1-AS1 associations Collection (Entity type)	Associations for UBE2Q1-AS1_associations
	UBE2Q1-AS1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	UBE2Q1-AS1 Gene (Entity type)	ENSG00000229780 - UBE2Q1 antisense RNA 1
	GSE226285 3 V 0 GLUTATHIONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE168401 2 V 0 HARMINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 0 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE168745 H-7 JHH-7 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 12 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 3 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 4 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS

UBE2Q1-AS1 associations

Associations for UBE2Q1-AS1_associations

UBE2Q1-AS1 associations.tsv

A file from IDG as part of the Harmonizome project

UBE2Q1-AS1

ENSG00000229780 - UBE2Q1 antisense RNA 1

GSE226285 3 V 0 GLUTATHIONE HUMAN UP

A Gene Set from LINCS

GSE168401 2 V 0 HARMINE HUMAN DN

A Gene Set from LINCS

GSE111247 temozolomide LN-308 0 v 8 human up

A Gene Set from LINCS

GSE168745 H-7 JHH-7 0 v 1 human dn

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 12 v 5 human up

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 3 v 7 human up

A Gene Set from LINCS

GSE239844 crizotinib 4 v 9 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.